Skip to content
PubMed This is a summary of 13 peer-reviewed journal articles Updated
Nephrology

Standard of Care: Medications and Daily Management

At a Glance

The standard treatment for APRT deficiency is daily, lifelong use of medications called XOR inhibitors, such as allopurinol or febuxostat. These drugs successfully stop new 2,8-DHA crystals from forming and protect your kidneys, though they cannot dissolve existing stones.

The diagnosis of APRT deficiency is a victory because the treatment is exceptionally effective. While the damage caused by 2,8-DHA crystals is serious, it can be completely halted—and in some cases, kidney function can even improve—with consistent daily management [1][2].

The Core Treatment: XOR Inhibitors

The most critical part of managing APRT deficiency is taking a medication called a xanthine oxidoreductase (XOR) inhibitor [1]. These drugs work by blocking the specific enzyme (XOR) that turns adenine into the harmful, insoluble 2,8-DHA crystals [1][3].

There are two primary medications used:

  • Allopurinol: Usually the first-line treatment, it has been used for decades and is very effective at reducing 2,8-DHA levels [1][4].
  • Febuxostat: A newer medication that is often used if allopurinol causes side effects or if a patient has significant kidney impairment [5][6]. It is sometimes more potent at clearing crystals at lower doses [6].

Safety Warning: While these medications are lifesaving for the kidneys, they can rarely cause severe allergic skin reactions (like Allopurinol Hypersensitivity Syndrome). If you ever develop a skin rash, fever, or blistering while taking these medications, stop the medication and contact a doctor immediately. For patients of certain descents (especially Asian or African), doctors may order a genetic test (HLA-B*58:01) before starting allopurinol to ensure it is safe for you.

Finding Your “Perfect Dose”

Treatment for APRT deficiency is not “one-size-fits-all.” Your doctor will titrate (adjust) your dose based on how your body responds [5].

The goal of treatment is the complete disappearance of 2,8-DHA crystals from your urine [5][6].

  1. Start: You will begin on a standard dose of allopurinol or febuxostat.
  2. Monitor: During the titration phase, you may be asked to provide urine samples frequently (e.g., weekly or monthly). Your doctor will perform a urine sediment exam to look for crystals [7].
  3. Adjust: If crystals are still present, the dose is increased. Once the optimal dose is found, crystals can clear from the urine within a matter of days or weeks [5][6].
  4. Blood Work: You will also have regular blood tests to check your kidney health [8][9].

What About Existing Stones?

It is crucial to understand that while XOR inhibitors prevent new crystals from forming, they will not dissolve existing 2,8-DHA stones. Because 2,8-DHA is highly insoluble and unaffected by urine pH, existing stones may remain in the kidneys [10]. If these stones cause blockages, pain, or recurrent infections, they may require surgical removal (such as lithotripsy or endoscopic surgery).

The Importance of Lifelong Adherence

This medication is not like an antibiotic that you take for a week; it is a lifelong commitment [9].

  • Rapid Return: If you stop taking your medication, the XOR enzyme will immediately begin creating 2,8-DHA again. Crystals can start reforming in your kidneys within a matter of days [11].
  • Silent Damage: Even if you don’t feel a painful kidney stone, “silent” crystals can still cause microscopic scarring in your kidney tissue [9][12].

Fluids and Diet: Breaking the Uric Acid Myth

Because APRT deficiency is so frequently confused with uric acid stones, patients are often mistakenly told to follow a strict “low-purine diet.”

  • The Truth About Diet: Unlike uric acid stones, the production of 2,8-DHA is driven almost entirely by your body’s internal cellular turnover, not by the food you eat. Strict dietary purine restrictions are generally ineffective and cause unnecessary stress [13].
  • High Fluid Intake: The only vital lifestyle change is drinking plenty of water (typically aiming for 2–3 liters a day). This keeps your urine diluted, making it much harder for crystals to clump together [11][12].

Common questions in this guide

What is the best medication for APRT deficiency?
The primary treatment for APRT deficiency involves medications called xanthine oxidoreductase (XOR) inhibitors, such as allopurinol or febuxostat. These drugs block the enzyme that turns adenine into harmful 2,8-DHA crystals, stopping new stones from forming.
How will my doctor know if my medication dose is correct?
Your doctor will regularly examine your urine under a microscope to look for 2,8-DHA crystals. If crystals are still present, your medication dose will be increased until the crystals completely disappear from your urine.
Will allopurinol or febuxostat dissolve my existing kidney stones?
No, these medications prevent new crystals from forming but cannot dissolve existing 2,8-DHA stones. If your current stones cause pain, recurrent infections, or blockages, you may need a procedure like lithotripsy or endoscopic surgery to remove them.
Can I stop taking my medication once my kidney stones are gone?
No, treatment for APRT deficiency is a lifelong commitment. If you stop taking your medication, your body will immediately start forming harmful 2,8-DHA crystals again. These crystals can silently damage your kidney tissue even if you do not feel any pain.
Do I need to follow a low-purine diet for APRT deficiency?
No, a strict low-purine diet is not necessary or effective. The harmful crystals in APRT deficiency are created by your body's internal cellular processes, not by the food you eat. The most important lifestyle change you can make is drinking plenty of water every day to keep your urine diluted.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Is allopurinol or febuxostat the better option for me based on my current level of kidney function?
  2. 2.What is the timeline for titrating my dose? Will I be providing urine samples weekly or monthly while we find the right amount?
  3. 3.Are we doing the HLA-B*58:01 genetic screening before I start allopurinol to ensure I am not at high risk for an allergic reaction?
  4. 4.If my current stones do not dissolve, at what point should we consider surgical options like lithotripsy or endoscopy to remove them?
  5. 5.What are the specific signs of a medication reaction (like a rash) that mean I should call your office immediately?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (13)
  1. 1

    A rare cause of urolithiasis in an infant: Answers.

    Koyun M, Sancaktar M, Aksoy GK, et al.

    Pediatric nephrology (Berlin, Germany) 2021; (36(7)):2067-2068 doi:10.1007/s00467-020-04910-y.

    PMID: 33459934
  2. 2

    2,8-dihyroxyadenine (DHA) crystalline nephropathy: A case report.

    Rather JI, Fatima M, Wani MM, et al.

    Clinical nephrology. Case studies 2025; (13()):37-40 doi:10.5414/CNCS111590.

    PMID: 40182129
  3. 3

    Activation of AMP-Activated Protein Kinase by Adenine Alleviates TNF-Alpha-Induced Inflammation in Human Umbilical Vein Endothelial Cells.

    Cheng YF, Young GH, Lin JT, et al.

    PloS one 2015; (10(11)):e0142283 doi:10.1371/journal.pone.0142283.

    PMID: 26544976
  4. 4

    Kidney Transplant Outcomes in Patients With Adenine Phosphoribosyltransferase Deficiency.

    Runolfsdottir HL, Palsson R, Agustsdottir IMS, et al.

    Transplantation 2020; (104(10)):2120-2128 doi:10.1097/TP.0000000000003088.

    PMID: 31880754
  5. 5

    Urinary Crystals with 2,8-Dihydroxyadeninuria.

    Mizuno S

    Internal medicine (Tokyo, Japan) 2021; (60(6)):963 doi:10.2169/internalmedicine.5939-20.

    PMID: 33055485
  6. 6

    Febuxostat for the Prevention of Recurrent 2,8-dihydroxyadenine Nephropathy due to Adenine Phosphoribosyltransferase Deficiency Following Kidney Transplantation.

    Nanmoku K, Kurosawa A, Shinzato T, et al.

    Internal medicine (Tokyo, Japan) 2017; (56(11)):1387-1391 doi:10.2169/internalmedicine.56.8142.

    PMID: 28566603
  7. 7

    A virtuous diagnostic and therapeutic roadmap triggered by a motivated and skilful urinary sediment examination.

    Garigali G, Marra G, Rizzo V, et al.

    Clinica chimica acta; international journal of clinical chemistry 2019; (492()):23-25 doi:10.1016/j.cca.2019.01.026.

    PMID: 30707895
  8. 8

    In vivo longitudinal 920 nm two-photon intravital kidney imaging of a dynamic 2,8-DHA crystal formation and tubular deterioration in the adenine-induced chronic kidney disease mouse model.

    Choi J, Choi MS, Jeon J, et al.

    Biomedical optics express 2023; (14(4)):1647-1658 doi:10.1364/BOE.485187.

    PMID: 37078028
  9. 9

    Kidney Disease in Adenine Phosphoribosyltransferase Deficiency.

    Runolfsdottir HL, Palsson R, Agustsdottir IM, et al.

    American journal of kidney diseases : the official journal of the National Kidney Foundation 2016; (67(3)):431-8.

    PMID: 26724837
  10. 10

    A case of 2,8-DHA crystalline nephropathy caused by adenine phosphoribosyltransferase deficiency: diagnosis and treatment.

    Kunou M, Yamaguchi M, Takahashi H, et al.

    CEN case reports 2023; (12(3)):329-334 doi:10.1007/s13730-022-00768-1.

    PMID: 36576711
  11. 11

    2,8-Dihydroxyadenine Nephropathy Identified as Cause of End-Stage Renal Disease After Renal Transplant.

    George SA, Al-Rushaidan S, Francis I, et al.

    Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation 2017; (15(5)):574-577 doi:10.6002/ect.2015.0096.

    PMID: 27447713
  12. 12

    Recurrence of crystalline nephropathy after kidney transplantation in APRT deficiency and primary hyperoxaluria.

    Bollée G, Cochat P, Daudon M

    Canadian journal of kidney health and disease 2015; (2()):31 doi:10.1186/s40697-015-0069-2.

    PMID: 26380104
  13. 13

    Current kidney function parameters overestimate kidney tissue repair in reversible experimental kidney disease.

    Klinkhammer BM, Buchtler S, Djudjaj S, et al.

    Kidney international 2022; (102(2)):307-320 doi:10.1016/j.kint.2022.02.039.

    PMID: 35483527

This page provides educational information on medications and daily management strategies for APRT deficiency. Always consult your nephrologist or prescribing doctor before modifying your medication dose or treatment plan.

Get notified when new evidence is published on Adenine phosphoribosyltransferase deficiency.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.